BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN17235 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN17235\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07753148-11302@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20310505
DTEND;VALUE=DATE:20310506
SUMMARY:REGN17235: Phase 1 readout est. (NCT07753148)
DESCRIPTION:REGN17235\, phase 1.\nStudy: Safety and Tolerability of REGN172
 35 in Adult Participants With Clonal Cytopenia of Undetermined Significanc
 e and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation\nEstimated pri
 mary completion: 5 May 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/regn17235#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07753148
URL:https://assetmemo.bio/drug/regn17235#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
